Nitric oxide-producing hydrogel materials

Details Nitric oxide-producing hydrogel materials Nitric oxide-producing hydrogel materials

2006-05-30

2006-05-30

Azpuru, Carlos A. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Implant or insert

C424S486000

Reexamination Certificate

active

07052711

ABSTRACT:
Hydrogels releasing or producing NO, most preferably polymerizable biodegradable hydrogels capable of releasing physiological amounts of NO for prolonged periods of time, are applied to sites on or in a patient in need of treatment thereof for disorders such as restenosis, thrombosis, asthma, wound healing, arthritis, penile erectile dysfunction or other conditions where NO plays a significant role. The polymeric materials can be formed into films, coatings, or microparticles for application to medical devices, such as stents, vascular grafts and catheters. The polymeric materials can also be applied directly to biological tissues and can be polymerized in situ. The hydrogels are formed of macromers, which preferably include biodegradable regions, and have bound thereto groups that are released in situ to elevate or otherwise modulate NO levels at the site where treatment is needed. The macromers can form a homo or hetero-dispersion or solution, which is polymerized to form a hydrogel material, that in the latter case can be a semi-interpenetrating network or interpenetrating network. Compounds to be released can be physically entrapped, covalently or ionically bound to macromer, or actually form a part of the polymeric material. The hydrogel can be formed by ionic and/or covalent crosslinking. Other active agents, including therapeutic, prophylactic, or diagnostic agents, can also be included within the polymeric material.

REFERENCES:
patent: 4526938 (1985-07-01), Churchill et al.
patent: 4716203 (1987-12-01), Casey et al.
patent: 4741337 (1988-05-01), Smith et al.
patent: 4957744 (1990-09-01), della Valle et al.
patent: 4987744 (1991-01-01), Handley et al.
patent: 5410016 (1995-04-01), Hubbell et al.
patent: 5508317 (1996-04-01), Müller
patent: 5665840 (1997-09-01), Pöhlmann et al.
patent: 5807927 (1998-09-01), Stockinger et al.
patent: 5849839 (1998-12-01), Hubbell et al.
patent: 5849841 (1998-12-01), Mühlebach et al.
patent: 5900433 (1999-05-01), Igo et al.
patent: 5910316 (1999-06-01), Keefer et al.
patent: 5932674 (1999-08-01), Müller
patent: 5939489 (1999-08-01), Müller
patent: 6011077 (2000-01-01), Müller
patent: 6262206 (2001-07-01), Nesvadba et al.
patent: 6299604 (2001-10-01), Ragheb et al.
patent: WO 96/32136 (1996-10-01), None
Bohl et al., “Nitric oxide-generating polymers reduce platelet adhesion and smooth muscle cell proliferation”, Biomaterials, 2000, 2273-2278, vol. 21.
Bohl et al., “Nitric Oxide-Releasing Materials for the Prevention of Thrombosis and Restenosis”, Proceed. Int'l. Sym. Control. Rel. Bioact. Mater., 2000, 143-144, vol. 27.
Bohl et al., “Nitric Oxide Producing Materials: A Potential Therapy for Thrombosis and Restenosis”, Proceed. Int'l. Sym. Control. Rel. Bioact. Mater., 1999, 56-57, vol. 26.
Cohn et al, “Biodegradable PEO/PLA block polymers”, J. Biomed. Mater. Res., 1988, 993-1009, vol. 22.
Cooke et al., “Antiatherogenic Effects of L-Arginine in the Hypercholesterolemic Rabbit”, J. Clin. Invest., 1992, 1168-1172, vol. 90.
De Graaf et al., “Nitric Oxide Functions as an Inhibitor of Platelet Adhesion Under Flow Conditions”, Circulation, 1992, 2284-2290, vol. 85.
De Meyer et al., “Effect of Nitric Oxide Donors on Neointima Formation and Vascular Reactivity in the Collared Carotid Artery of Rabbits”, J. Cardiovasc. Res., 1995, 272-279, vol. 26.
Diodati et al., “Complexes of Nitric Oxide with Nucleophiles as Agents for the Controlled Biological Release of Nitric Oxide: Hemodynamic Effect in the Rabbit”, J. Cardiovasc. Pharm., 1993, 287-292, vol. 22.
Diodati et al., “Complexes of Nitric Oxide with Nucleophiles as Agents for the Controlled Biological Release of Nitric Oxide: Antiplatelet Effect”, Throm. Haem., 1993, 654-658, 1993.
Garg et al., “Nitric Oxide-Generating Vasodilators and 8-Bromo Cyclic Guanosine Monophosphate Inhibit Mitogenesis and Proliferation of Cultured Rat Vascular Smooth Muscle Cells”, J. Clin. Invest., 1989, 1774-1777, vol. 83.
Greenhalgh, “The Role of Growth Factors in Wound Healing”, J. Trauma, 1996, 159-167, vol. 41.
Heller et al., “Nitric Oxide Inhibits Proliferation of Human Endothelial Cells via a Mechanism Independent of cGMP”, Atherosclerosis, 1999, 49-57, vol. 144.
Hern et al., “Incorporation of Adhesion Peptides into Nonadhesive Hydrogels Useful for Tissue Resurfacing”, J. Biomed. Mater. Res., 1998, 266-276, vol. 39.
Holland et al., Polymers for Biodegradable Medical Devices. 1. The Potential of Polyesters as Controlled Macromolecular Release Systems, 1986, 155-180, vol. 4.
Ignarro et al., “Mechanism of Vascular Smooth Muscle Relaxation by Organic Nitrates, Nitrites, Nitroprusside and Nitric Oxide: Evidence for the Involvement of S-Nitrosothiols as Active Intermediates”, J. Pharmacol. Exp. Ther., 1981, 739-749, vol. 218.
Kwon et al., “Inhibition of Tumor Cell Ribonucleotide Reductase by Macrophage-derived Nitric Oxide”, J. Exp. Med., 1991, 761-767, vol. 174.
Lefer et al., “Antineutrophil and Myocardial Protecting Actions of a Novel Nitric Oxide Donor After Acute Myocardial Ischemia and Reperfusion in Dogs”, Circulation, 1993, 2337-2350, vol. 88.
Legrand et al., “Preclinical Promise of Becaplermin (rhPDGF-BB) in Wound Healing”, Am. J. Surg., 1998, 48S-54S, vol. 176.
Lepoivre et al., “Inactivation of Ribonucleotide Reductase by Nitric Oxide”, Biochem. Biophys. Res. Comm., 1991, 442-448, vol. 179.
Mann et al., “Tethered-TGF-β Increases Extracellular Matrix Production of Vascular Smooth Muscle Cells”, Biomaterials, 2001, 439-444, vol. 22.
Maragos et al., “Nitric Oxide/Nucleophile Complexes Inhibit thein VitroProliferation of A375 Melanoma Cells via Nitric Oxide Release”, Cancer Res., 1993, 564-568, vol. 53.
Martinez-De Jesus et al., “Randomized Single-Blind Trial of Topical Ketanserin for Healing Acceleration of Diabetic Foot Ulcers”, Arch. Med. Res., 1997, 95-99, vol. Spring 28 (1) (Abstract only).
Mathews et al., “Biological Activity of S-Nitrosothiols: The Role of Nitric Oxide”, J. Pharmacol. Exp. Therap., 1993, 1529-1537, vol. 267.
Moro et al., “cGMP Mediates the Vascular and Platelet Actions of Nitric Oxide: Confirmation Using an Inhibitor of the Soluble Guanylyl Cyclase”, Proc. Natl. Acad. Sci. USA, 1996, 1480-1485, vol. 93.
Rodomski et al., “Comparative Pharmacology of Endothelium-Derived Relaxing Factor, Nitric Oxide and Prostacyclin in Platelets”, Br. J. Pharmacol., 1987, 181-187, vol. 92.
Sarkar et al., “Nitric Oxide Inhibition of Endothelial Cell Mitogenesis and Proliferation”, Surgery, 1995, 274-279, vol. 118.
Sawhney et al., “Rapidly Degraded Terpolymers of dl-Lactide, Glycolide, and ε-Caprolactone with Increased Hydrophilicity by Copolymerization with Polyethers”, J. Biomed. Res., 1990, 1397-1411, vol. 24.
Scott-Burden et al., “Extracellular Matrix: Differential Influence on Growth and Biosynthesis Patterns of Vascular Smooth Muscle Cells from SHR and WKY Rats”, J. Cell Physiol., 1989, 267-274, vol. 141.
Scott-Burden et al., “Genetically Engineered Smooth Muscle Cells as Linings to Improve the Biocompatibility of Cardiovascular Prostheses”, Circulation, 1996, II235-238, vol. 94 (9 Suppl.).
Smith et al., “Nitric Oxide-Releasing Polymers Containing the [N(O)NO] Group”, J. Med. Chem., 1996, 1148-1156, vol. 39.
Spilizewski et al., “The Effect of Hydrocortisone Acetate Loaded Poly (DL-Lactide) Films on the Inflammatory Response”, J. Control. Rel., 1985, 197-203, vol. 2.
Stuehr et al., “Nitric Oxide—A Macrophage Product Responsible for Cytostasis and Respiratory Inhibition in Tumor Target Cells”, J. Exp. Med., 1989, 1543-1555, vol. 169.
Williams et al., Safety and Tolerability of Intravenous-to-Oral Treatment and Single-Dose Intravenous or

Affiliated with

Also associated with

Rating

Nitric oxide-producing hydrogel materials does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nitric oxide-producing hydrogel materials, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitric oxide-producing hydrogel materials will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3582233